Traumatic brain injury (TBI) is a common health concern that affects thousands to millions of people in the United States and worldwide (Thurman et al., 1999; Cassidy et al., 2004; Centers for Disease Control and Prevention, 2010). The consequences of TBI manifest in a time-dependent manner and unfold in phases starting immediately following the traumatic event. The primary damage to the brain tissue is followed by a series of secondary molecular and cellular events that can either cause reversible or permanent cell damage resulting in cell death, tissue loss and, in time, neurodegeneration. In many cases, changes in subjects’ cognition and personality induced by a mild TBI (mTBI) spontaneously resolve over time; however, this is not always true (Thornhill et al., 2000; Arciniegas et al., 2005). Some individuals are left with long-lasting deficits in cognition and executive functions, which adversely affect the patient’s and their families’ quality of life. mTBI is hence hugely costly to health care systems internationally and incurs a substantial national financial and quality of life burden (Thurman et al., 1999; Dillahunt-Aspillaga et al., 2013; Qadeer et al., 2017).

Presently, there are no FDA-approved first-choice medicines for the treatment of TBI (Margulies and Hicks, 2009; Diaz-Arrastia et al., 2014). This is a critical roadblock in the effective clinical management of TBI. A lack of robust biomarkers to quantitatively assess TBI severity and predict its time-dependent progression with activation of secondary injury cascades, as well as its potential resolution, has proven to be a significant impediment in the development of effective treatments. Several studies have recently provided positive headway by suggesting candidate biomarkers for TBI severity and prediction of patient outcomes. Candidate biomarkers for moderate-to-severe TBI measured in serum/plasma or cerebrospinal fluid (CSF) reflect damage to various brain cell types and include neuronal-specific ubiquitin C-terminal hydrolase L1 (UCH-L1, Korley et al., 2018; Mondello et al., 2011), neuronal-specific neurofilament light (NFL, Korley et al., 2018; Shahim et al., 2016; Olczak et al., 2018), astrocytic-specific glial fibrillary acidic protein (GFAP, Mondello et al., 2011; Olczak et al., 2018) and oligodendrocyte-specific myelin basic protein (MBP, Olczak et al., 2018).

Regarding S100 calcium binding protein B (S100B), there have been mixed data on its utility in TBI; Golden et al., 2018 and Kövesdi et al., 2010 found it to predict poor outcomes following severe TBI, whereas Shahim et al., 2016 determined that it was unhelpful in predicting patient outcomes (Golden et al., 2018; Kövesdi et al., 2010; Shahim et al., 2016). Potential biomarkers for mTBI have likewise been investigated, and plasma/serum levels of NFL, UCH-L1 and tau (a microtubule-associated protein) were observed to be potentially useful (Joseph et al., 2018; Shahim et al., 2017). Chen and co-workers observed elevations in RNA transcripts of genes implicated in Alzheimer’s disease (Cyclin Dependent Kinase 2, Casein Kinase 1 Alpha 1 and Cathepsin D) in saliva from patients with mild, concussion-related TBI (Cheng et al., 2019). While progress has been made for identifying biomarkers for moderate-to-severe TBI, more effort needs to be applied in identifying effective biomarkers of mTBI, which comprises about 85% of all TBI events.

Our laboratories have utilized a murine closed head weight drop model of mTBI, modified from the Marmarou model (Marmarou et al., 1994), that mimics numerous features of the human condition (Zohar et al., 2003; Milman et al., 2005; Tashlykov et al., 2007; Tweedie et al., 2007). Several of our prior studies focused on hippocampal gene expression changes, which allowed us to identify key molecular pathways triggered by a single mTBI insult that were successfully mitigated by pharmacological treatment (Tweedie et al., 2013a; Tweedie et al., 2013b; Tweedie et al., 2016a; Tweedie et al., 2016b).

The present study follows up on this earlier research by evaluating changes in brain tissue proteins induced by a single mTBI event. Based on our prior gene array evidence highlighting the involvement of inflammatory pathways in mTBI and the work of others (Israelsson et al., 2008; Israelsson et al., 2009; Tweedie et al., 2016b), we quantified the levels of approximately 200 inflammation-related proteins in ipsilateral cortical tissue to define time-dependent changes. Ipsilateral cortical tissues were obtained from one sham group and mTBI animals euthanized at 8, 24, 48, 72 and 96 hr and 7, 14 and 30 days post-mTBI. We observed numerous differences in inflammatory proteins between mTBI-challenged and sham tissue samples, 23 proteins were significantly different from sham protein levels in four or more of the eight different sample time points. Notably, the proteins FASL, CXCL16, Fractalkine, IL-1 ra and MIG were significantly reduced and IL-17E, GAS-1 and VEGF-B significantly elevated by mTBI, in six to seven of the eight time points. Gene ontology pathways mapped from proteins that changed over time were associated with pathological and physiological processes and several were linked with pathways that may be beneficial or pathological, depending on which proteins were altered at the specific time points. To discover non-invasive biomarkers for mTBI, we additionally assessed the protein contents of neuronally enriched extracellular vesicles (NEVs) extracted from the plasma of a subset of mTBI-challenged mice. Correlations in protein changes between cortical tissue and CNS EV cargo proteins were explored.

The TBI animal model used in this study produces a mild diffuse form of injury with no focal lesion or disruption of the blood-brain barrier (BBB). Prior studies utilizing this model have identified evidence of neuronal cell loss as early as 3 days post-injury, and neurobehavioral deficits that develop over time, typically starting from 7 days that remain present 30 days after the initial brain injury. We previously identified alterations in hippocampal expression of multiple genes, many of which suggest a strong involvement of inflammation and inflammatory pathways following the induction of TBI (Tweedie et al., 2013a; Tweedie et al., 2016a; Tweedie et al., 2016b; Tweedie et al., 2013b). In the present study, we investigated changes in brain tissue proteins related to inflammation and inflammatory processes over an extended time period, from 8 hr to 30 days post-mTBI, with eight different sampling time points following the induction of a single mTBI.

As no behavioral or immunohistochemical measures were evaluated in the mTBI animals over the time span of the current study, our only evidence of TBI-induced changes and trends in measures between the sham and mTBI animals can be made by comparisons of the mTBI and sham cortical and NEV proteins. Findings illustrate that the induction of the injury can induce marked, lasting changes in cytokine/chemokine proteins in mouse cortical tissue. We identify a subset of proteins that were observed to be significantly altered by mTBI in four or more of the eight sample time points (in all 23 proteins). Of these proteins a more focused smaller set of eight (Table 1A) were identified that were significantly altered in six to seven of the eight different time points evaluated following injury. It is possible that several of the TBI-altered proteins identified here may prove useful as biomarkers of TBI. Although these proteins warrant further evaluations to validate them as biomarkers of mTBI, this is beyond the scope of the current study. It is important to understand that following mTBI both cellular physiological and pathological processes are taking place, as evidenced by the mapping of several of the significantly altered cortical derived proteins to pathways associated with pro-survival - physiological, and cell death - pathological processes. In this study, three different proteins stood out as potential candidate proteins for development as drug targets. They were novel in the context of traumatic brain injury and displayed consistent increases or reductions during the study time frame. GAS-1 and VEGF-B were increased, and CXCL16 was reduced compared to sham levels. Of these three proteins GAS-1 and CXCL16 may be the best options for drug target validation, both proteins are known to modulate neuronal cell death involving glutamate excitotoxicity, a common feature of brain injuries (Globus et al., 1995; Mellström et al., 2002; Rosito et al., 2012; Rosito et al., 2014; Sun et al., 2016; Wang et al., 2016a; Zarco et al., 2012) and as such may make them ideal candidate drug targets for evaluation. While there are no direct reports of the actions of VEGF-B on the traumatized brain, it is tempting to speculate that the homeostatic and pro-neurogenesis properties of the protein would be ripe for exploration in TBI (Nag et al., 2002; Sun et al., 2004; Sun et al., 2006). After completion of studies aimed at defining if the observed protein changes were pathological or physiological compensatory in nature following mTBI, these proteins may make for good candidate drug targets. Pre-clinical studies manipulating the proteins followed up with sensitive behavioral and immunohistchemical analysis will be vital in the validation of each protein as novel drug targets in mTBI.

Complex TBI-induced changes in cellular protein expressions and time-dependent changes in cortical proteins were observed in our study that mapped to common pathways related to pathological processes, namely apoptosis, Fas signaling and Alzheimer’s disease. Commonly recurring cell survival - physiological pathways were related to angiogenesis, EGF receptor, PDFG, GDNF and Wnt signaling systems. Based on the mapping of the significantly changed proteins there appeared to be a balance between cell death and cell survival pathways as early as 8 hr and then up to 14 days after injury. It is interesting that by the last sample collection time point in our study, 30 days post-mTBI, the cell death associated pathways were not observed to be active, yet physiological and immunological pathways were observed. While we are not able to comment on the time between 14 days and 30 days, these data suggest that in this mild model of TBI a transition in the balance between proteins responsible for cell death and cell survival has occurred. Future work can be directed at identifying which proteins change between these times after a mTBI.

Comparing our data with data derived from brain RNA-Seq analysis (Zhang et al., 2014) showed that of the 23 proteins most frequently changed over time, that 10 of the proteins displayed preferential expression in microglia over astrocytes and neurons (VEGF-B, CXCL16, IL-1ra, progranulin, MIP-1a, RANTES, Galectin-1, TWEAK R, also MADCAM-1 and IL-1 r4 albeit with low expression levels in all cell types). While the proteins GAS-1, GITR and IL-17E showed preferential expression in astrocytes (GITR and IL-17E were of low expression levels in all three cell types). Fractalkine and FASL both showed a preferential expression in neurons over the other cells, yet FASL expression was low for brain tissue. Of the remaining proteins, eight proteins were observed to be expressed at very low levels in brain and showed no preferential expression between microglia, astrocytes and neurons (MIG, MBL-2, CRP, E-cadherin, IL-20, CD30 L, CD40 L and TCA-3). Based on these observations, one can suggest that the microglial cells are chiefly responsible for the generation of the proteins changed over time in the mouse cortical tissue post-mTBI and, as such, may make a good candidate for more focused drug target interventions. To establish a treatment regimen that targets microglia following a TBI of any level of severity, it is important to realize that the microglial cell possesses a dual character where it can be linked with both protective and damaging cellular responses. The dual nature of the microglial cell has been thought of as being either M1 or M2, a classification borrowed from that of peripheral macrophages (Mills et al., 2000), which are linked to pro-inflammatory or anti-inflammatory functions, respectively. Classically, it is believed that both forms of cells express distinct markers exclusively depending on the status of the cell. In more recent times, data relating to CNS microglia markers has provided evidence that a microglial cell may simultaneously express markers classically associated with M1 and M2 phenotypes. A study examining gene expressions and proteins following an open head controlled cortical impact (CCI) TBI (Morganti et al., 2016), provides such evidence of mixed populations of microglial cells. Morganti and co-workers describe the expression of numerous proteins that were formerly associated with one form or the other (M1/M2) in the same cells. Several of the proteins they describe were observed in our antibody array data, for example those associated with M1: MIG (CXCL9), CXCL16, and those associated with M2: Fractalkine (CX3CL1), IL-17E also known as IL-25, and TGFβ1, to name a few. These observations further suggest that even in mild models of TBI, such as our model, that brain tissue microglia present with mixed phenotypes following injury.

Two proteins were significantly changed compared to sham at seven of the eight times after mTBI; specifically, Fas Ligand (FASL) and VEGF-B. FASL is a protein bound to the cell membrane or cleaved from it to generate a soluble protein that has a role in apoptosis. Here, we show that cortical tissue levels of FASL were reduced as early as 8 hr following mTBI, protein levels reached their lowest point at 48 hr with a partial recovery that appeared to be maintained until 14 days following mTBI. Our findings differ somewhat to those of others who have investigated FAS signaling following TBI. Beer and co-workers have shown evidence of increased immunostaining of FAS/FASL in an open head, moderate CCI model of TBI in rats (Beer et al., 2000), a finding in contrast to our observations from our mild closed head model of TBI. Topcu and co-workers described increased FAS/FASL immunostaining in rat brain following a closed head weight drop at 24 hr after injury (Topcu et al., 2013). Zhang and co-workers demonstrated changes in FAS receptor protein levels, but no changes in FASL protein in postmortem human severe TBI compared to non-TBI control tissues (Zhang et al., 2003). These conflicting reports may be due to differences in TBI severity and mechanisms of injury induction. It is noteworthy that Ziebell and co-workers reported that mice with mutated FAS receptor and disrupted FAS signaling subjected to open scalp, closed head weight drop (a model of TBI similar to ours) had better neurological outcomes and pathological changes when compared to wild-type animals (Ziebell et al., 2011). This suggests that attenuating FAS signaling may be beneficial to the traumatized brain. It is possible that the reduction in tissue FASL, seen herein, is a homeostatic compensatory response to mTBI. This hypothesis may be addressed by further studies employing pharmacological intervention(s) with proven efficacy in our mild model of TBI.

The growth factor vascular endothelial growth factor-B (VEGF-B) displayed a more complex pattern of expression. Its protein level was significantly increased at 8 and 24 hr following TBI; however, although also elevated versus sham animals at 48 hr after injury, levels did not attain statistical significance at this time. Notably, from 72 hr up to and including 30 days following mTBI, VEGF-B protein levels were again significantly elevated. The roles of VEGF-B in physiology and disease is nicely described in review by Bry and co-workers (Bry et al., 2014). They indicate that VEGF-B has anti-apoptotic effects and is beneficial in cardiovascular disease and neuroprotective in the setting of cerebral ischemia and animal models of Amyotrophic Lateral Sclerosis and Parkinson’s disease. They also suggest that the described benefits of VEGF-B in CNS are meditated by the receptor VEGFR1 located on neurons and that the expression of VEGF-B may be regulated at the tissue level by mitochondrial metabolic processes. Somewhat in confliction with these observations are those from studies by Rothhammer and co-workers (Rothhammer et al., 2018). They describe a complex relationship between microglial derived TGF-alpha and VEGF-B on the pathological role of astrocytes in a murine model of multiple sclerosis, with VEGF-B exacerbating the disease pathology. Interestingly, Rothhammer and co-workers provided evidence that dietary metabolites of tryptophan were able to regulate microglial activation and the generation of VEGF-B, suggesting a role of the gut microbiome in the regulation of brain inflammation. Presently there are no reports documenting altered levels of VEGF-B in the setting of TBI. The protein is constitutively expressed in the vascular endothelium, and it may have a beneficial role in stabilizing or maintaining BBB function. The genetic deletion of VEGF-B is reported to exacerbate neurological disease, while elevations in brain vascular levels of VEGF-B may provide a compensatory restorative action aimed at stabilizing TBI-induced BBB damage. Additionally, the protein has been shown to display pro-neurogenesis effects in rodent brain (Nag et al., 2002; Sun et al., 2004; Sun et al., 2006). In the light of this information, it is likely that VEGF-B elevations observed in this study are a homeostatic compensatory response aimed at minimizing TBI-induced disturbances in BBB function and stabilizing the brain microenvironment. A reduction in BBB integrity, subtle changes in blood flow, and vasogenic edema are common following TBI and can drive the activation of proteases, initiation of inflammatory pathways and production of reactive oxygen species to further cause tissue damage (Alluri et al., 2015). Time-dependent studies in rats subjected to CCI injury demonstrated a biphasic reduction in BBB integrity, peaking initially at 4 to 6 hr after injury and then at 3 days (Başkaya et al., 1997), which largely coincides with the VEGF-B biphasic changes in our mTBI model.

Six proteins were significantly different at six of the eight time points after mTBI compared to sham; specifically, CXCL16; Fractalkine, IL-1 ra and MIG were lower, IL-17E and GAS-1 were higher after mTBI compared to sham. This may be the first study to report alterations in cortical protein levels of the chemokine CXCL16 following mTBI. CXCL16 was shown to be consistently reduced starting 24 hr following mTBI and remained so for up to 14 days following injury. Reports of the involvement of CXCL16 in brain injury are limited; however, this protein has been reported to have potential neuropathological or neuroprotective roles in neurological disorders. For example, in the setting of multiple sclerosis CXCL16 has been linked with neuropathology (Hendrickx et al., 2013); yet it has also been shown to possess neuroprotective properties in the setting of stroke and in vitro excitotoxicity studies. In this regard, CXCL16 can attenuate the neurotoxic effects of glutamate on neurons (Rosito et al., 2012; Rosito et al., 2014). Excitotoxicity caused by glutamate is a common observation in most forms of brain insult, including TBI (Globus et al., 1995). The decline in CXCL16 seen in our study suggests a loss of protection from excitotoxicity as a causative factor for mTBI-induced neurodegeneration.

Fractalkine (CX3CL1) is a chemokine that can exist as a soluble or a membrane bound protein that binds exclusively to one receptor (CXC3R1). The protein has been shown to have a role in the regulation of the activity of microglial cells. In the present study, reductions in fractalkine cortical levels, compared to sham levels, were first observed at 24 hr after TBI and followed a bi-phasic response peaking at 48 hr, and then at 96 hr after TBI. Reduced protein levels were maintained for up to 14 days following injury. There is conflicting evidence regarding the physiological role of fractalkine in brain, some studies suggest that it tends to push microglial cells towards a more activated phenotype (Cardona et al., 2006), while others to a more neuroprotective one (Mizuno et al., 2003; Gaetani et al., 2013). The consequences of fractalkine signaling on microglial phenotype appear to be directed, in part, by the nature of the CNS injury and whether it is an acute or chronic insult. Fractalkine has been shown to be neuroprotective in vitro, against challenges with glutamate or N-methyl-D-aspartate in hippocampal neurons (Lauro et al., 2015; Limatola et al., 2005). Cardona et al., 2006 demonstrated that deletion of the fractalkine receptor from microglia exacerbated neurotoxicity when microglia were activated by various stimuli. Febinger and co-workers (Febinger et al., 2015) illustrated that fractalkine signaling played a role in TBI pathology following a CCI injury. In that study, they used a fractalkine receptor knock-out animal and showed that a lack of fractalkine signaling led to fewer TBI-related functional deficits (apoptosis and neuronal cell death) compared to wild-type mice, at early times after injury (less than 15 days), while at later times (approximately 30 days following injury) the transgenic animals showed more deficits compared to wild-type animals. This finding suggests that microglial phenotypes are strongly sensitive to time-dependent alterations in fractalkine signaling, shifting microglial phenotypes from a more anti-inflammatory (neuroprotective) state to a more pro-inflammatory (neurotoxic) state at later times. This interpretation is further supported by a study by Zanier and co-workers using a similar, yet slightly more severe model of CCI brain injury than that used in the Febinger study (Zanier et al., 2016). Clausen and co-workers illustrated significant elevations of fractalkine in cerebrospinal fluid after a fluid percussive injury in rats (Clausen et al., 2019). Subsequent to stroke, fractalkine mRNA levels and immunohistochemical reactive signals for fractalkine were observed to be reduced in the infarct area, but increased in tissues surrounding the infarct core (Tarozzo et al., 2002). In contrast to our observations, Rancan and co-workers observed no changes in brain tissue levels of fractalkine in a mouse closed head injury model somewhat similar in nature to our model (Rancan et al., 2004).

The cytokine IL-1 receptor antagonist (IL-1 ra) was markedly reduced compared to sham levels at 24 hr after TBI. Changes in levels of this cytokine were more complex than those observed for other proteins; there appeared to be a bi-phasic response. IL-1 ra protein levels were significantly reduced compared to sham levels even on day 30 after injury. In the setting of TBI there are conflicting reports on the utility of employing IL-1 ra as a potential treatment of TBI, some suggest that treatment can push microglial cells to a more activated pro-inflammatory phenotype, with others indicating protective effects in the CNS following TBI (Toulmond and Rothwell, 1995; Knoblach and Faden, 2000; Helmy et al., 2014; Helmy et al., 2016; Semple et al., 2017; Sun et al., 2017; Tehranian et al., 2002). In a mouse model of mTBI, not dissimilar to ours, Tehranian and co-workers observed that mice overexpressing brain IL-1 ra fared better than wild-type animals in overall neurological assessments, and possessed reduced levels of pro-inflammatory cytokines following TBI. Our observations with mTBI show that IL-1 ra levels are reduced compared to sham protein levels. Our findings indirectly add further credence to the premise that augmentation of IL-1 ra, in the setting of mTBI, may push the brain micro-environment toward a beneficial state that may provide a useful treatment modality in the clinic. Shiozaki and co-works reported elevated CSF concentrations of IL-1 ra after TBI in humans that depended on its severity, with higher concentrations observed after more severe TBIs (Shiozaki et al., 2005).

This may be the first report of TBI causing a sustained reduction of the chemokine MIG (also known as CXCL9). MIG/CXCL9 is thought to play a beneficial role in precursor neuronal cell development, survival and integration into existing neural networks (Turbic et al., 2011). A reduction of MIG may reflect the commonly observed altered neurogenesis after TBI (Ngwenya and Danzer, 2018). Wang and co-workers reported that altered states of neurogenesis following TBI were, in part, dependent on the nature and severity of the injury; reporting severity-dependent changes in neural stem cell proliferation, and the generation of immature and then mature neurons following graded CCI injuries (Wang et al., 2016b).

Interestingly, the signaling protein growth arrest-specific 1 (GAS-1) is highly expressed in the brain and has been associated with neuronal cell death (Mellström et al., 2002; Sun et al., 2016; Wang et al., 2016a; Zarco et al., 2012). Wang and co-workers illustrated that GAS-1 protein levels in vitro, were increased by a challenge with glutamate (a hallmark feature of TBI) and that elevated levels of GAS-1 protein may interfere with the protective effects of glial cell neurotrophic factor (GDNF, Wang et al., 2016a). Our studies revealed that GAS-1 protein levels were elevated as early as 8 hr following mTBI, peaking at 72 hr and remaining elevated for up to 7 days after injury. In this light, the effects of mTBI on GAS-1 protein levels and the functional properties of this protein underscore it as a prospective novel drug treatment target and also as a monitoring biomarker for TBI.

In the present study, cortical protein levels of IL-17E (also known as IL-25), were robustly elevated by 48 hr after mTBI, remaining so even at 30 days after injury. Reports of the involvement of the pro-inflammatory protein IL-17E in the setting of TBI are absent. However, IL-17E/IL-25 has been shown to be elevated in plasma in a neuroinflammatory disorder, neuromyelitis optica spectrum disorder (Zhang et al., 2018). There is evidence that IL-25 is generated in brain by capillary endothelial cells and that this cytokine may, like VEGF-B, play a beneficial homeostatic role in the brain by maintaining the BBB integrity and, in addition, may drive microglial cells towards an anti-inflammatory phenotype (Sonobe et al., 2016; Maiorino et al., 2013). Elevations in IL-25 have been observed in cortical and hippocampal tissues of patients with epilepsy (Kan et al., 2012).

Whereas the changes in proteins described above may provide interesting drug targets to either mitigate or monitor TBI, it is likely that differences in their onset time, duration of regulation, as well as dynamic range in their level of change, may suggest different contexts of use as biomarkers. For example, due to the early pattern of mTBI-induced changes in the proteins FASL, CXCL16 and GAS-1, these may have utility as biomarkers for early TBI. IL-17E (IL-25) presented with a more delayed regulation after TBI, and may thus provide insight into later stages of TBI development and possible responses to pharmacological interventions in relation to injury recovery. Similarly, VEGF-B was significantly increased at 8 and 24 hr, but not at 48 hr, but then again at all time points from 72 hr onwards, and may, like 1 L-17E, be useful for following changes in brain tissue responses to injury or pharmacological interventions at mid to late time points. In contrast, IL-1 ra and fractalkine both showed marked changes in protein levels; however, the patterns were complex bi-phasic responses. Such time-dependent changes in protein levels can still provide utility as biomarkers of disease progression or drug response, but should probably not be interpreted individually, but as part of a panel of other biomarkers to provide insight into the nature of the biological processes that are active at different times (Parolo et al., 2018).

It is noteworthy that several of the proteins identified to be changed by a single mTBI over a 30 day period have been described to modulate neuronal cell death mediated by excitotoxic stimulation, such as by glutamate. This is significant, since excessive release of glutamate following brain injury is considered a hallmark feature of brain trauma (Globus et al., 1995). CXCL16 was reduced in our model, and has been shown to be involved in cellular communications between neurons and glial cells, and to possess neuroprotective properties that can attenuate the neurotoxic effects of glutamate in vitro and excitotoxic stimulation in vivo (Rosito et al., 2012; Rosito et al., 2014). Similarly, fractalkine, which was shown to be reduced after mTBI in our study, has been shown to be neuroprotective, in vitro, against challenge with glutamate or N-methyl-D-aspartate (Lauro et al., 2015; Limatola et al., 2005). The protein GAS-1 was elevated in our model of mTBI; it is interesting that Wang and co-workers illustrated that GAS-1 protein levels were up-regulated in vitro by challenge with glutamate and that elevated levels of GAS-1 protein may interfere with the protective effects of glial cell neurotrophic factor (GDNF, Wang et al., 2016a). These observations give added weight to the importance of glutamate excitotoxicity following brain trauma, and further provide hopeful drug targets for evaluation in additional TBI models and in the clinic.

Changes in NEV cargo proteins over time were relatively small compared to changes in cortex, and only moderate correlations were observed. This finding is, perhaps, not surprising as we assessed EVs enriched for neuronal origin and it is widely considered that microglia and astrocytes generate the largest amounts of cytokines and chemokines of brain cell types; nevertheless, neurons also produce them to some extent (Gadient and Otten, 1994; Ringheim et al., 1995). It is, however, noteworthy that one of the significantly regulated NEV proteins did show some similarity between the two sample types. The protein, c-reactive protein (CRP), is regulated by inflammation and is present in neurons (Yasojima et al., 2000). It displayed significant increases in cortex over time, with non-significant elevations in later time points in CNS EV-derived samples. There are numerous reports linking neurotrauma and TBI with elevated CRP and poor patient outcomes (Bengzon et al., 2003; Hergenroeder et al., 2008; Gullo et al., 2011; Ishikawa et al., 1999; Sharma et al., 2017). For the most part, reported CRP measurements were derived from patient plasma/serum and not from EVs. It is possible that evaluation of CRP could prove to be useful singly or within a panel of markers of mTBI, and represents one of several candidate biomarkers meriting further evaluation.

In the present study, it is not possible to say to what extent the changes in proteins observed in the cortical arrays are explicitly due to reductions or increases in protein synthesis or if the changes are due to a loss or increase in cell numbers in the injured cortex. It is, however, worth considering that our prior work using this mild model of TBI with a 30 g weight has provided evidence of diffuse neuronal cell degeneration observed at 72 hr following mTBI, additionally we have observed losses of neurons at 7 and 30 days following mTBI (Bader et al., 2019a, Bader et al., 2019b; Benady et al., 2018; Lecca et al., 2019; Rubovitch et al., 2015). As such, we are not able to exclude the possibility that the reductions in the proteins observed in the cortical arrays are due to a loss of cells in the animal brains and not solely due to a reduction in expression of the proteins. However, it is important to note that numerous proteins were shown to be increased compared to sham tissue levels, suggesting that there are complex interactions between multiple cell types in the brain tissue microenvironment.

The work of others in the field of TBI has nicely shown that with more severe levels of injuries the greater are the functional deficits and cellular markers of pathology. This has been shown to be the case in such models as moderate fluid percussion injury (FPI) and moderate CCI TBI (Shojo et al., 2010; Yu et al., 2009). Yu et al., show that different grades of CCI injury result in severity-dependent losses in brain tissue and impaired measures of cognition and motor function. Shojo and co-workers showed time-dependent changes in gene expressions relating to inflammation that peaked shortly after PFI, that preceded the development of hallmark features of apoptosis at later times. Compared to our model of TBI, these are more severe models requiring the generation of craniotomies, with the subsequent disruption of the BBB. It is interesting to note that in our model of mild TBI, Tashlykov and co-workers showed that increasing the severity of injury by increasing the weights used to induce the TBI (drop height of 80 cm with weights from 5 to 30 g) resulted in a greater response regarding the induction of markers of apoptosis and neurodegeneration (Tashlykov et al., 2007; Tashlykov et al., 2009). Thus, it is possible that the use of different weights in our model of TBI may alter the time course and magnitude of the changes in proteins observed in our antibody arrays, this would require additional studies to verify this hypothesis. Also, it may be worth considering the effects of skull fractures in weight drop models as described by Zvejniece and co-workers. They describe work in an open head, close skull weight drop model (drop height of 8 cm with a weight of 90 g) examining the effects of different weight cone diameters (2 or 5 mm) on inducing TBIs associated with frequent skull fractures in mice (Zvejniece et al., 2020). Their observations describe worsened functional outcomes and more pronounced inflammatory responses for animals that received the weight drops which resulted in the occurrence of skull fractures. The authors suggest that under reported skull fractures may, in part, explain the frequently observed large variations seen in behavioral and biochemical outcome markers present in weight drop models of TBI. Our model does not use stereotactic instrumentation and, as a result, this leads to variability where the weight connects with the animal skull. Hence, we and others have observed variability in functional and biochemical measures in our model, which have been described previously by Israelsson and co-workers (Israelsson et al., 2009) and observed in this study (see Figure 5) and are in accord with human TBI.

Potential weaknesses of this study are related to a lack of behavioral assessments in the same animals from which tissue samples were derived. However, based on our prior studies in separate cohorts of alike mice, we demonstrated that mTBI, as used herein, resulted in consistent cognitive impairments involving both spatial (Y-maze) and visual (novel object recognition) tasks when evaluated at either 7 or 30 days after injury (Zohar et al., 2003; Milman et al., 2005; Tweedie et al., 2013a; Tweedie et al., 2016a). A further potential weakness may be related to a lack of corresponding immunohistochemical data; however, again our prior studies in alike cohorts of mTBI-challenged mice have consistently demonstrated the development of diffuse neuronal loss, neuroinflammation and astrogliosis (Bader et al., 2019a; Lecca et al., 2019; Baratz et al., 2015). As the animals used in this study were not perfused with buffer prior to euthanasia, there will have been a small volume of blood present in the dissected cortical tissues (Kaliss and Pressman, 1950; Greig et al., 1988). As such, we are not able to exclude the possibility that a small component of the array data may be derived from the mouse blood. Technical limitations of the SOMAscan assay primarily reside in the fact that the detection system is not able to distinguish between post-translationally modified and non-modified proteins, and thus measurements reflect total protein abundances. Also, the assay is more qualitative than quantitative in nature. The strength of the assay lies in the capacity to assess a substantial number of target proteins at one time from a single sample.

The overall aim of the present study was to identify novel biomarkers related to inflammatory proteins following a single mild TBI in mice that may translate to human clinical TBI. A frequently used, powerful tool available to aid in biomarker discovery is mass-spectrometry (MS). A significant feature of MS is that the technique may provide information on thousands of proteins in one sample providing an unbiased approach to biomarker discovery. Interestingly, MS can be semi-quantitative or quantitative which involves the incorporation of specific proteins of interest to act as internal standards, an intervention that makes this aspect of MS more of a biased detection method rather than an unbiased approach. As all techniques have limitations, possible drawbacks of MS detection lie in sample preparation which can be time consuming and often requires several processing steps that may lead to over manipulation of the samples. Often high abundant background proteins may mask low abundance proteins of interest, which may then introduce artifacts in measuring low abundance proteins of relevance to the biology of the samples. Additionally, one sample can only be processed with MS at one time, and thus when working with large numbers of samples it would be time consuming to use MS technology. We chose to study the effects of a single mild TBI on inflammatory proteins over an extended time period in mouse cortical tissues, based on prior observations made in our animal model of mTBI (Israelsson et al., 2009; Tweedie et al., 2016b). With our focus on inflammatory proteins, we chose to exclude commonly investigated markers of TBI like NFL, UCH-L1 and GFP as, while they are worthy proteins of interest in TBI, they are not inflammatory in nature. Current available multiplex ELISA-based technologies targeting inflammatory proteins are limited to 10 or so targets. To investigate larger numbers of inflammatory proteins would require large quantities of samples. Hence, due to the limited availability of sample material from mouse cortical tissue, we elected to use a panel of quantitative antibody arrays. Potential limitations of antibody arrays may be related to the number of capture antibody spots attached to the array chip. Our arrays had 50 targets per chip, requiring the use of several different chips to investigate 200 proteins. It is interesting to note that a main utility of antibody arrays lies in the combination of high affinity, highly specific antibody pairs that allows for the sensitive detection of low and high abundance target proteins in complex sample lysate mixtures without the need to remove higher concentration background proteins. While this biased approach of biomarker investigation has inherent limitations, namely that we will miss out on proteins not present on the arrays, we were successful in our approach as we were able to demonstrate lasting changes in eight proteins, 5 of which are novel in the setting of TBI (FASL, VEGF-B, CXCL16, MIG, GAS-1, IL-17E, IL-1 ra and Fractalkine). While both MS and antibody array technologies have advantages and disadvantages, and both require subsequent target validation by alternative methods, it is likely that the combination of the unbiased MS and biased antibody array methods can complement each other to be used together to advance the discovery of novel proteins related to disease diagnosis, progression and potential drug target engagement.

The necessity of extracting tissue at specific time points underlies the difficulties in designing a study to both measure time-dependent changes in brain proteins to determine how they may regulate brain neuropathology and also assess animal behavior. These difficulties may be overcome by the use of non-invasive CNS sampling methods, such as plasma derived neuronal extracellular vesicle protein cargo assessments. While these combined proteomic approaches were undertaken to provide insight into new possible biomarkers for mTBI, and the identification of functional pathways derived from significantly changed cortical proteins, additional studies are clearly required with a more focused aim to understand how pharmacological interventions may impact the levels of these candidate biomarkers in both rodent brain and NEVs from humans and animals, in parallel with cognitive, behavioral and neuropathological assessments. Correlations between the common proteins observed on the cortical arrays and the SOMAscan assay platform were weak. This is most likely caused by the small changes seen in the NEV proteins and the low animal numbers. More focused studies are required to investigate correlations between NEV cargo and cortical proteins following mTBI. Only with such information will the full utility of NEVs as non-invasive sources of possible biomarkers of TBI be confirmed, and only at this point we will be able to make any recommendations for candidate human markers of TBI and drug target engagement.

Mouse mTBI studies were conducted at the Intramural Research Program of the National Institute on Aging, Baltimore, MD, USA. Specifically, male CD-1 mice, 6–8 weeks old (weighing approximately 30 g) were housed five to a cage under a 12 hr light/dark cycle (constant temperature 22°C) with food (Purina rodent chow) and water ad libitum. Experimental animal protocols were approved by the Animal Care and Use Committee of the Intramural Research Program, National Institute on Aging (438-TGB-2022) and were in compliance with the guidelines for animal experimentation of the National Research Council (Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011) and the National Institutes of Health (DHEW publication 85–23, revised, 1995). A minimal number of mice were used for the study and well-being evaluations were applied to ensure a lack of potential suffering.

Experimental mTBI was induced using the concussive, closed-scalp head trauma device described previously (Zohar et al., 2003; Milman et al., 2005; Tashlykov et al., 2007; Tweedie et al., 2007). Mice were fully anesthetized by inhalation anesthesia in a closed isoflurane vaporizer chamber. After full anesthesia had been achieved, each animal was placed under a metal tube device with the opening positioned directly over the animal’s head just anterior to the left ear (to provide mild injury to the left cerebral hemisphere). Each mouse was held in a manner such that the force of impact to the skull generated anterior-lateral movements without any rotational movements, analogous to those that occur during closed head injury in automobile accidents. The injury was induced by dropping a 1 cm diameter blunted flat cylindrical metal weight (30 g), inside a metal tube device (inner diameter 13 mm) from a height of 80 cm. This injury is analogous to two humans of the same weight clashing heads. Sham (control) animals were subjected to the same procedure, but without the weight being dropped. After the induction of the injury or sham procedure, mice were placed back in their home cage to allow for recovery from the anesthesia. Mice were randomly assigned to receive either mTBI or sham injury, and those in the former group were then randomly assigned to be euthanized at different post-injury times (Table 3). Due to the observations that even in this mild model of TBI, TBI-induced alterations in brain cells occur in both the ipsilateral and contralateral hemispheres (Tashlykov et al., 2007; Tashlykov et al., 2009), we have included absolute sham operated control animals for comparison with mTBI animal protein measurements. In the design of this study, we chose to include one group of sham animals to be used to compare the effects of mTBI over time rather than including a sham group for each mTBI time point. In brief, we studied a total of 18 sham animals; 12 animals euthanized at each of 8, 24 and 72 hr, 7 and 14 days post-mTBI; eight animals euthanized at each of 48 and 96 hr post-mTBI and four animals euthanized at 30 days post-mTBI evaluation. Selection of animal numbers was based on our prior studies (Israelsson et al., 2009; Tweedie et al., 2007; Tweedie et al., 2016a; Tweedie et al., 2016b). Whole blood was collected from animals that were fully anesthetized and euthanized by decapitation, blood was placed in heparinized tubes. Plasma was prepared from the blood and NEVs were isolated from the plasma. All animals were euthanized in the same way to avoid introducing sampling variations.

All data generated by US NIH funded research is available to the public, the data generated in this study is available to the public. The data used to generate the figures in the manuscript are provided as source data files.

1. 1. Alluri H
   2. Wiggins-Dohlvik K
   3. Davis ML
   4. Huang JH
   5. Tharakan B

   (2015) Blood-brain barrier dysfunction following traumatic brain injury

   Metabolic Brain Disease 30:1093–1104.

   https://doi.org/10.1007/s11011-015-9651-7

   • PubMed
   • Google Scholar
2. 1. Arciniegas DB
   2. Anderson CA
   3. Topkoff J
   4. McAllister TW

   (2005) Mild traumatic brain injury: a neuropsychiatric approach to diagnosis, evaluation, and treatment

   Neuropsychiatric Disease and Treatment 1:311–327.

   https://doi.org/10.1176/appi.focus.20160025

   • PubMed
   • Google Scholar
3. 1. Bader M
   2. Li Y
   3. Lecca D
   4. Rubovitch V
   5. Tweedie D
   6. Glotfelty E
   7. Rachmany L
   8. Kim HK
   9. Choi HI
   10. Hoffer BJ
   11. Pick CG
   12. Greig NH
   13. Kim DS

   (2019a) Pharmacokinetics and efficacy of PT302, a sustained-release exenatide formulation, in a murine model of mild traumatic brain injury

   Neurobiology of Disease 124:439–453.

   https://doi.org/10.1016/j.nbd.2018.11.023

   • PubMed
   • Google Scholar
4. 1. Bader M
   2. Li Y
   3. Tweedie D
   4. Shlobin NA
   5. Bernstein A
   6. Rubovitch V
   7. Tovar-Y-Romo LB
   8. DiMarchi RD
   9. Hoffer BJ
   10. Greig NH
   11. Pick CG

   (2019b) Neuroprotective effects and treatment potential of incretin mimetics in a murine model of mild traumatic brain injury

   Frontiers in Cell and Developmental Biology 7:356.

   https://doi.org/10.3389/fcell.2019.00356

   • PubMed
   • Google Scholar
5. 1. Baratz R
   2. Tweedie D
   3. Wang JY
   4. Rubovitch V
   5. Luo W
   6. Hoffer BJ
   7. Greig NH
   8. Pick CG

   (2015) Transiently lowering tumor necrosis factor-α synthesis ameliorates neuronal cell loss and cognitive impairments induced by minimal traumatic brain injury in mice

   Journal of Neuroinflammation 12:45.

   https://doi.org/10.1186/s12974-015-0237-4

   • PubMed
   • Google Scholar
6. 1. Başkaya MK
   2. Rao AM
   3. Doğan A
   4. Donaldson D
   5. Dempsey RJ

   (1997) The biphasic opening of the blood-brain barrier in the cortex and Hippocampus after traumatic brain injury in rats

   Neuroscience Letters 226:33–36.

   https://doi.org/10.1016/s0304-3940(97)00239-5

   • PubMed
   • Google Scholar
7. 1. Beer R
   2. Franz G
   3. Schöpf M
   4. Reindl M
   5. Zelger B
   6. Schmutzhard E
   7. Poewe W
   8. Kampfl A

   (2000) Expression of fas and fas ligand after experimental traumatic brain injury in the rat

   Journal of Cerebral Blood Flow & Metabolism 20:669–677.

   https://doi.org/10.1097/00004647-200004000-00004

   • PubMed
   • Google Scholar
8. 1. Benady A
   2. Freidin D
   3. Pick CG
   4. Rubovitch V

   (2018) GM1 ganglioside prevents axonal regeneration inhibition and cognitive deficits in a mouse model of traumatic brain injury

   Scientific Reports 8:13340.

   https://doi.org/10.1038/s41598-018-31623-y

   • PubMed
   • Google Scholar
9. 1. Bengzon J
   2. Grubb A
   3. Bune A
   4. Hellström K
   5. Lindström V
   6. Brandt L

   (2003) C-reactive protein levels following standard neurosurgical procedures

   Acta Neurochirurgica 145:667–671.

   https://doi.org/10.1007/s00701-003-0083-5

   • PubMed
   • Google Scholar
10. 1. Bry M
    2. Kivelä R
    3. Leppänen VM
    4. Alitalo K

    (2014) Vascular endothelial growth factor-B in physiology and disease

    Physiological Reviews 94:779–794.

    https://doi.org/10.1152/physrev.00028.2013

    • PubMed
    • Google Scholar
11. 1. Cardona AE
    2. Pioro EP
    3. Sasse ME
    4. Kostenko V
    5. Cardona SM
    6. Dijkstra IM
    7. Huang D
    8. Kidd G
    9. Dombrowski S
    10. Dutta R
    11. Lee J-C
    12. Cook DN
    13. Jung S
    14. Lira SA
    15. Littman DR
    16. Ransohoff RM

    (2006) Control of microglial neurotoxicity by the fractalkine receptor

    Nature Neuroscience 9:917–924.

    https://doi.org/10.1038/nn1715

    • Google Scholar
12. 1. Cassidy JD
    2. Carroll L
    3. Peloso P
    4. Borg J
    5. von Holst H
    6. Holm L
    7. Kraus J
    8. Coronado V

    (2004) Incidence, risk factors and prevention of mild traumatic brain injury: results of the who collaborating centre task force on mild traumatic brain injury

    Journal of Rehabilitation Medicine 36:28–60.

    https://doi.org/10.1080/16501960410023732

    • Google Scholar
13. Report

    1. Centers for Disease Control and Prevention

    (2010) National Hospital Discharge Survey (NHDS), 2010; National Hospital Ambulatory Medical Care Survey (NHAMCS), 2010; National Vital Statistics System (NVSS), 2010. All Data Sources Are Maintained by the CDC National Center for Health Statistics

    CDC.

    https://www.cdc.gov/nchs/nhds/nhds_publications.htm

    • Google Scholar
14. 1. Cheng Y
    2. Pereira M
    3. Raukar N
    4. Reagan JL
    5. Queseneberry M
    6. Goldberg L
    7. Borgovan T
    8. LaFrance WC
    9. Dooner M
    10. Deregibus M
    11. Camussi G
    12. Ramratnam B
    13. Quesenberry P

    (2019) Potential biomarkers to detect traumatic brain injury by the profiling of salivary extracellular vesicles

    Journal of Cellular Physiology 234:14377–14388.

    https://doi.org/10.1002/jcp.28139

    • PubMed
    • Google Scholar
15. 1. Clausen F
    2. Marklund N
    3. Hillered L

    (2019) Acute inflammatory biomarker responses to diffuse traumatic brain injury in the rat monitored by a novel microdialysis technique

    Journal of Neurotrauma 36:201–211.

    https://doi.org/10.1089/neu.2018.5636

    • PubMed
    • Google Scholar
16. 1. Diaz-Arrastia R
    2. Kochanek PM
    3. Bergold P
    4. Kenney K
    5. Marx CE
    6. Grimes CJ
    7. Loh LT
    8. Adam LT
    9. Oskvig D
    10. Curley KC
    11. Salzer W

    (2014) Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the department of defense neurotrauma pharmacology workgroup

    Journal of Neurotrauma 31:135–158.

    https://doi.org/10.1089/neu.2013.3019

    • PubMed
    • Google Scholar
17. 1. Dillahunt-Aspillaga C
    2. Jorgensen-Smith T
    3. Ehlke S
    4. Sosinski M
    5. Monroe D
    6. Thor J

    (2013) Traumatic brain injury: unmet support needs of caregivers and families in Florida

    PLOS ONE 8:e82896.

    https://doi.org/10.1371/journal.pone.0082896

    • PubMed
    • Google Scholar
18. 1. Febinger HY
    2. Thomasy HE
    3. Pavlova MN
    4. Ringgold KM
    5. Barf PR
    6. George AM
    7. Grillo JN
    8. Bachstetter AD
    9. Garcia JA
    10. Cardona AE
    11. Opp MR
    12. Gemma C

    (2015) Time-dependent effects of CX3CR1 in a mouse model of mild traumatic brain injury

    Journal of Neuroinflammation 12:154.

    https://doi.org/10.1186/s12974-015-0386-5

    • PubMed
    • Google Scholar
19. 1. Gadient RA
    2. Otten U

    (1994) Identification of interleukin-6 (IL-6)-expressing neurons in the cerebellum and Hippocampus of normal adult rats

    Neuroscience Letters 182:243–246.

    https://doi.org/10.1016/0304-3940(94)90807-9

    • PubMed
    • Google Scholar
20. 1. Gaetani P
    2. Pisano P
    3. Solinas G
    4. Colombo P
    5. Destro A
    6. Levi D
    7. Aimar E
    8. Rodriguez R
    9. Baena Y
    10. Allavena P

    (2013)

    Immunohistohemical expression of the chemokine fractalkine and its receptor in the human brain cortex after severe traumatic brain injury and brain hemorrhage

    Journal of Neurosurgical Sciences 57:55–62.

    • PubMed
    • Google Scholar
21. 1. Globus MY
    2. Alonso O
    3. Dietrich WD
    4. Busto R
    5. Ginsberg MD

    (1995) Glutamate release and free radical production following brain injury: effects of posttraumatic hypothermia

    Journal of Neurochemistry 65:1704–1711.

    https://doi.org/10.1046/j.1471-4159.1995.65041704.x

    • PubMed
    • Google Scholar
22. 1. Goetzl EJ
    2. Kapogiannis D
    3. Schwartz JB
    4. Lobach IV
    5. Goetzl L
    6. Abner EL
    7. Jicha GA
    8. Karydas AM
    9. Boxer A
    10. Miller BL

    (2016) Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease

    The FASEB Journal 30:4141–4148.

    https://doi.org/10.1096/fj.201600816R

    • PubMed
    • Google Scholar
23. 1. Goetzl EJ
    2. Nogueras-Ortiz C
    3. Mustapic M
    4. Mullins RJ
    5. Abner EL
    6. Schwartz JB
    7. Kapogiannis D

    (2018) Deficient neurotrophic factors of CSPG4-type neural cell exosomes in alzheimer disease

    FASEB Journal 20:fj201801001.

    https://doi.org/10.1096/fj.201801001

    • Google Scholar
24. 1. Golden N
    2. Mahadewa TGB
    3. Aryanti C
    4. Widyadharma IPE

    (2018) S100B serum level as a mortality predictor for traumatic brain injury: a Meta-Analysis

    Open Access Macedonian Journal of Medical Sciences 6:2239–2244.

    https://doi.org/10.3889/oamjms.2018.432

    • PubMed
    • Google Scholar
25. 1. Greig NH
    2. Soncrant TT
    3. Wozniak KM
    4. Rapoport SI

    (1988)

    Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration

    The Journal of Pharmacology and Experimental Therapeutics 245:574–580.

    • PubMed
    • Google Scholar
26. 1. Grubbs FE

    (1950) Sample criteria for testing outlying observations

    The Annals of Mathematical Statistics 21:27–58.

    https://doi.org/10.1214/aoms/1177729885

    • Google Scholar
27. 1. Gullo JS
    2. Bertotti MM
    3. Silva CC
    4. Schwarzbold M
    5. Diaz AP
    6. Soares FM
    7. Freitas FC
    8. Nunes J
    9. Pinheiro JT
    10. Morato EF
    11. Prediger RD
    12. Linhares MN
    13. Walz R

    (2011) Hospital mortality of patients with severe traumatic brain injury is associated with serum PTX3 levels

    Neurocritical Care 14:194–199.

    https://doi.org/10.1007/s12028-010-9462-y

    • PubMed
    • Google Scholar
28. 1. Helmy A
    2. Guilfoyle MR
    3. Carpenter KL
    4. Pickard JD
    5. Menon DK
    6. Hutchinson PJ

    (2014) Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial

    Journal of Cerebral Blood Flow & Metabolism 34:845–851.

    https://doi.org/10.1038/jcbfm.2014.23

    • PubMed
    • Google Scholar
29. 1. Helmy A
    2. Guilfoyle MR
    3. Carpenter KLH
    4. Pickard JD
    5. Menon DK
    6. Hutchinson PJ

    (2016) Recombinant human interleukin-1 receptor antagonist promotes M1 microglia biased cytokines and chemokines following human traumatic brain injury

    Journal of Cerebral Blood Flow & Metabolism 36:1434–1448.

    https://doi.org/10.1177/0271678X15620204

    • PubMed
    • Google Scholar
30. 1. Hendrickx DA
    2. Koning N
    3. Schuurman KG
    4. van Strien ME
    5. van Eden CG
    6. Hamann J
    7. Huitinga I

    (2013) Selective upregulation of scavenger receptors in and around demyelinating Areas in multiple sclerosis

    Journal of Neuropathology & Experimental Neurology 72:106–118.

    https://doi.org/10.1097/NEN.0b013e31827fd9e8

    • PubMed
    • Google Scholar
31. 1. Hergenroeder G
    2. Redell JB
    3. Moore AN
    4. Dubinsky WP
    5. Funk RT
    6. Crommett J
    7. Clifton GL
    8. Levine R
    9. Valadka A
    10. Dash PK

    (2008) Identification of serum biomarkers in brain-injured adults: potential for predicting elevated intracranial pressure

    Journal of Neurotrauma 25:79–93.

    https://doi.org/10.1089/neu.2007.0386

    • PubMed
    • Google Scholar
32. 1. Ishikawa K
    2. Tanaka H
    3. Takaoka M
    4. Ogura H
    5. Shiozaki T
    6. Hosotsubo H
    7. Shimazu T
    8. Yoshioka T
    9. Sugimoto H

    (1999) Granulocyte colony-stimulating factor ameliorates life-threatening infections after combined therapy with barbiturates and mild hypothermia in patients with severe head injuries

    The Journal of Trauma: Injury, Infection, and Critical Care 46:999–1008.

    https://doi.org/10.1097/00005373-199906000-00004

    • PubMed
    • Google Scholar
33. 1. Israelsson C
    2. Bengtsson H
    3. Kylberg A
    4. Kullander K
    5. Lewén A
    6. Hillered L
    7. Ebendal T

    (2008) Distinct cellular patterns of upregulated chemokine expression supporting a prominent inflammatory role in traumatic brain injury

    Journal of Neurotrauma 25:959–974.

    https://doi.org/10.1089/neu.2008.0562

    • PubMed
    • Google Scholar
34. 1. Israelsson C
    2. Wang Y
    3. Kylberg A
    4. Pick CG
    5. Hoffer BJ
    6. Ebendal T

    (2009) Closed head injury in a mouse model results in molecular changes indicating inflammatory responses

    Journal of Neurotrauma 26:1307–1314.

    https://doi.org/10.1089/neu.2008.0676

    • PubMed
    • Google Scholar
35. 1. Joseph JR
    2. Swallow JS
    3. Willsey K
    4. Lapointe AP
    5. Khalatbari S
    6. Korley FK
    7. Oppenlander ME
    8. Park P
    9. Szerlip NJ
    10. Broglio SP

    (2018) Elevated markers of brain injury as a result of clinically asymptomatic high-acceleration head impacts in high-school football Athletes

    Journal of Neurosurgery 1:1–7.

    https://doi.org/10.3171/2017.12.JNS172386

    • Google Scholar
36. 1. Kaliss N
    2. Pressman D

    (1950) Plasma and blood volumes of mouse organs, as determined with radioactive iodoproteins

    Experimental Biology and Medicine 75:16–20.

    https://doi.org/10.3181/00379727-75-18083

    • PubMed
    • Google Scholar
37. 1. Kan AA
    2. de Jager W
    3. de Wit M
    4. Heijnen C
    5. van Zuiden M
    6. Ferrier C
    7. van Rijen P
    8. Gosselaar P
    9. Hessel E
    10. van Nieuwenhuizen O
    11. de Graan PN

    (2012) Protein expression profiling of inflammatory mediators in human temporal lobe epilepsy reveals co-activation of multiple chemokines and cytokines

    Journal of Neuroinflammation 9:207.

    https://doi.org/10.1186/1742-2094-9-207

    • PubMed
    • Google Scholar
38. 1. Kiddle SJ
    2. Steves CJ
    3. Mehta M
    4. Simmons A
    5. Xu X
    6. Newhouse S
    7. Sattlecker M
    8. Ashton NJ
    9. Bazenet C
    10. Killick R
    11. Adnan J
    12. Westman E
    13. Nelson S
    14. Soininen H
    15. Kloszewska I
    16. Mecocci P
    17. Tsolaki M
    18. Vellas B
    19. Curtis C
    20. Breen G
    21. Williams SC
    22. Lovestone S
    23. Spector TD
    24. Dobson RJ

    (2015) Plasma protein biomarkers of Alzheimer's disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes

    Translational Psychiatry 5:e584.

    https://doi.org/10.1038/tp.2015.78

    • PubMed
    • Google Scholar
39. 1. Knoblach SM
    2. Faden AI

    (2000) Cortical interleukin-1 beta elevation after traumatic brain injury in the rat: no effect of two selective antagonists on motor recovery

    Neuroscience Letters 289:5–8.

    https://doi.org/10.1016/S0304-3940(00)01263-5

    • PubMed
    • Google Scholar
40. 1. Korley FK
    2. Yue JK
    3. Wilson DH
    4. Hrusovsky K
    5. Diaz-Arrastia R
    6. Ferguson AR
    7. Yuh EL
    8. Mukherjee P
    9. Wang KKW
    10. Valadka AB
    11. Puccio AM
    12. Okonkwo DO
    13. Manley GT

    (2018) Performance evaluation of a multiplex assay for simultaneous detection of four clinically relevant traumatic brain injury biomarkers

    Journal of Neurotrauma 36:182–187.

    https://doi.org/10.1089/neu.2017.5623

    • Google Scholar
41. 1. Kövesdi E
    2. Lückl J
    3. Bukovics P
    4. Farkas O
    5. Pál J
    6. Czeiter E
    7. Szellár D
    8. Dóczi T
    9. Komoly S
    10. Büki A

    (2010) Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics

    Acta Neurochirurgica 152:1–17.

    https://doi.org/10.1007/s00701-009-0463-6

    • PubMed
    • Google Scholar
42. 1. Lauro C
    2. Catalano M
    3. Di Paolo E
    4. Chece G
    5. de Costanzo I
    6. Trettel F
    7. Limatola C

    (2015) Fractalkine/CX3CL1 engages different neuroprotective responses upon selective glutamate receptor overactivation

    Frontiers in Cellular Neuroscience 8:472.

    https://doi.org/10.3389/fncel.2014.00472

    • Google Scholar
43. 1. Lecca D
    2. Bader M
    3. Tweedie D
    4. Hoffman AF
    5. Jung YJ
    6. Hsueh S-C
    7. Hoffer BJ
    8. Becker RE
    9. Pick CG
    10. Lupica CR
    11. Greig NH

    (2019) (-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice

    Neurobiology of Disease 130:104528.

    https://doi.org/10.1016/j.nbd.2019.104528

    • Google Scholar
44. 1. Limatola C
    2. Lauro C
    3. Catalano M
    4. Ciotti MT
    5. Bertollini C
    6. Di Angelantonio S
    7. Ragozzino D
    8. Eusebi F

    (2005) Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity

    Journal of Neuroimmunology 166:19–28.

    https://doi.org/10.1016/j.jneuroim.2005.03.023

    • PubMed
    • Google Scholar
45. 1. Maiorino C
    2. Khorooshi R
    3. Ruffini F
    4. Løbner M
    5. Bergami A
    6. Garzetti L
    7. Martino G
    8. Owens T
    9. Furlan R

    (2013) Lentiviral-mediated administration of IL-25 in the CNS induces alternative activation of microglia

    Gene Therapy 20:487–496.

    https://doi.org/10.1038/gt.2012.58

    • PubMed
    • Google Scholar
46. 1. Margulies S
    2. Hicks R

    (2009) Combination therapies for traumatic brain injury workshop leaders. Combination therapies for traumatic brain injury: prospective considerations

    Journal of Neurotrauma 26:925–939.

    https://doi.org/10.1089/neu.2008.0794

    • Google Scholar
47. 1. Marmarou A
    2. Foda MA
    3. van den Brink W
    4. Campbell J
    5. Kita H
    6. Demetriadou K

    (1994) A new model of diffuse brain injury in rats. Part I: pathophysiology and biomechanics

    Journal of Neurosurgery 80:291–300.

    https://doi.org/10.3171/jns.1994.80.2.0291

    • PubMed
    • Google Scholar
48. 1. Mellström B
    2. Ceña V
    3. Lamas M
    4. Perales C
    5. Gonzalez C
    6. Naranjo JR

    (2002) Gas1 is induced during and participates in excitotoxic neuronal death

    Molecular and Cellular Neuroscience 19:417–429.

    https://doi.org/10.1006/mcne.2001.1092

    • PubMed
    • Google Scholar
49. 1. Mi H
    2. Muruganujan A
    3. Huang X
    4. Ebert D
    5. Mills C
    6. Guo X
    7. Thomas PD

    (2019) Protocol update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0)

    Nature Protocols 14:703–721.

    https://doi.org/10.1038/s41596-019-0128-8

    • PubMed
    • Google Scholar
50. 1. Mills CD
    2. Kincaid K
    3. Alt JM
    4. Heilman MJ
    5. Hill AM

    (2000) M-1/M-2 macrophages and the Th1/Th2 paradigm

    The Journal of Immunology 164:6166–6173.

    https://doi.org/10.4049/jimmunol.164.12.6166

    • PubMed
    • Google Scholar
51. 1. Milman A
    2. Rosenberg A
    3. Weizman R
    4. Pick CG

    (2005) Mild traumatic brain injury induces persistent cognitive deficits and behavioral disturbances in mice

    Journal of Neurotrauma 22:1003–1010.

    https://doi.org/10.1089/neu.2005.22.1003

    • PubMed
    • Google Scholar
52. 1. Mizuno T
    2. Kawanokuchi J
    3. Numata K
    4. Suzumura A

    (2003) Production and neuroprotective functions of fractalkine in the central nervous system

    Brain Research 979:65–70.

    https://doi.org/10.1016/S0006-8993(03)02867-1

    • PubMed
    • Google Scholar
53. 1. Mondello S
    2. Papa L
    3. Buki A
    4. Bullock MR
    5. Czeiter E
    6. Tortella FC
    7. Wang KK
    8. Hayes RL

    (2011) Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study

    Critical Care 15:R156.

    https://doi.org/10.1186/cc10286

    • PubMed
    • Google Scholar
54. 1. Morganti JM
    2. Riparip LK
    3. Rosi S

    (2016) Call off the dog(ma): M1/M2 polarization is concurrent following traumatic brain injury

    PLOS ONE 11:e0148001.

    https://doi.org/10.1371/journal.pone.0148001

    • PubMed
    • Google Scholar
55. 1. Nag S
    2. Eskandarian MR
    3. Davis J
    4. Eubanks JH

    (2002) Differential expression of vascular endothelial growth factor-A (VEGF-A) and VEGF-B after brain injury

    Journal of Neuropathology & Experimental Neurology 61:778–788.

    https://doi.org/10.1093/jnen/61.9.778

    • PubMed
    • Google Scholar
56. 1. Ngwenya LB
    2. Danzer SC

    (2018) Impact of traumatic brain injury on neurogenesis

    Frontiers in Neuroscience 12:1014.

    https://doi.org/10.3389/fnins.2018.01014

    • PubMed
    • Google Scholar
57. 1. Olczak M
    2. Kwiatkowska M
    3. Niderla-Bielińska J
    4. Chutorański D
    5. Tarka S
    6. Wierzba-Bobrowicz T

    (2018) Brain-originated peptides as possible biochemical markers of traumatic brain injury in cerebrospinal fluid post-mortem examination

    Folia Neuropathologica 56:97–103.

    https://doi.org/10.5114/fn.2018.76613

    • PubMed
    • Google Scholar
58. 1. Parolo S
    2. Marchetti L
    3. Lauria M
    4. Misselbeck K
    5. Scott-Boyer MP
    6. Caberlotto L
    7. Priami C

    (2018) Combined use of protein biomarkers and network analysis unveils deregulated regulatory circuits in duchenne muscular dystrophy

    PLOS ONE 13:e0194225.

    https://doi.org/10.1371/journal.pone.0194225

    • PubMed
    • Google Scholar
59. 1. Qadeer A
    2. Khalid U
    3. Amin M
    4. Murtaza S
    5. Khaliq MF
    6. Shoaib M

    (2017) Caregiver's Burden of the Patients With Traumatic Brain Injury

    Cureus 9:e1590.

    https://doi.org/10.7759/cureus.1590

    • PubMed
    • Google Scholar
60. 1. Rancan M
    2. Bye N
    3. Otto VI
    4. Trentz O
    5. Kossmann T
    6. Frentzel S
    7. Morganti-Kossmann MC

    (2004) The chemokine fractalkine in patients with severe traumatic brain injury and a mouse model of closed head injury

    Journal of Cerebral Blood Flow & Metabolism 24:1110–1118.

    https://doi.org/10.1097/01.WCB.0000133470.91843.72

    • PubMed
    • Google Scholar
61. 1. Ringheim GE
    2. Burgher KL
    3. Heroux JA

    (1995) Interleukin-6 mRNA expression by cortical neurons in culture: evidence for neuronal sources of interleukin-6 production in the brain

    Journal of Neuroimmunology 63:113–123.

    https://doi.org/10.1016/0165-5728(95)00134-4

    • PubMed
    • Google Scholar
62. 1. Rosito M
    2. Deflorio C
    3. Limatola C
    4. Trettel F

    (2012) CXCL16 orchestrates Adenosine A3 receptor and MCP-1/CCL2 activity to protect neurons from excitotoxic cell death in the CNS

    Journal of Neuroscience 32:3154–3163.

    https://doi.org/10.1523/JNEUROSCI.4046-11.2012

    • PubMed
    • Google Scholar
63. 1. Rosito M
    2. Lauro C
    3. Chece G
    4. Porzia A
    5. Monaco L
    6. Mainiero F
    7. Catalano M
    8. Limatola C
    9. Trettel F

    (2014) Trasmembrane chemokines CX3CL1 and CXCL16 drive interplay between neurons, microglia and astrocytes to counteract pMCAO and excitotoxic neuronal death

    Frontiers in Cellular Neuroscience 8:193.

    https://doi.org/10.3389/fncel.2014.00193

    • PubMed
    • Google Scholar
64. 1. Rothhammer V
    2. Borucki DM
    3. Tjon EC
    4. Takenaka MC
    5. Chao CC
    6. Ardura-Fabregat A
    7. de Lima KA
    8. Gutiérrez-Vázquez C
    9. Hewson P
    10. Staszewski O
    11. Blain M
    12. Healy L
    13. Neziraj T
    14. Borio M
    15. Wheeler M
    16. Dragin LL
    17. Laplaud DA
    18. Antel J
    19. Alvarez JI
    20. Prinz M
    21. Quintana FJ

    (2018) Microglial control of astrocytes in response to microbial metabolites

    Nature 557:724–728.

    https://doi.org/10.1038/s41586-018-0119-x

    • PubMed
    • Google Scholar
65. 1. Rubovitch V
    2. Barak S
    3. Rachmany L
    4. Goldstein RB
    5. Zilberstein Y
    6. Pick CG

    (2015) The neuroprotective effect of salubrinal in a mouse model of traumatic brain injury

    NeuroMolecular Medicine 17:58–70.

    https://doi.org/10.1007/s12017-015-8340-3

    • PubMed
    • Google Scholar
66. 1. Sattlecker M
    2. Kiddle SJ
    3. Newhouse S
    4. Proitsi P
    5. Nelson S
    6. Williams S
    7. Johnston C
    8. Killick R
    9. Simmons A
    10. Westman E
    11. Hodges A
    12. Soininen H
    13. Kłoszewska I
    14. Mecocci P
    15. Tsolaki M
    16. Vellas B
    17. Lovestone S
    18. Dobson RJ
    19. AddNeuroMed Consortium

    (2014) Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology

    Alzheimer's & Dementia 10:724–734.

    https://doi.org/10.1016/j.jalz.2013.09.016

    • PubMed
    • Google Scholar
67. 1. Semple BD
    2. O'Brien TJ
    3. Gimlin K
    4. Wright DK
    5. Kim SE
    6. Casillas-Espinosa PM
    7. Webster KM
    8. Petrou S
    9. Noble-Haeusslein LJ

    (2017) Interleukin-1 receptor in seizure susceptibility after traumatic injury to the pediatric brain

    The Journal of Neuroscience 37:7864–7877.

    https://doi.org/10.1523/JNEUROSCI.0982-17.2017

    • PubMed
    • Google Scholar
68. 1. Shahim P
    2. Gren M
    3. Liman V
    4. Andreasson U
    5. Norgren N
    6. Tegner Y
    7. Mattsson N
    8. Andreasen N
    9. Öst M
    10. Zetterberg H
    11. Nellgård B
    12. Blennow K

    (2016) Serum neurofilament light protein predicts clinical outcome in traumatic brain injury

    Scientific Reports 6:36791.

    https://doi.org/10.1038/srep36791

    • PubMed
    • Google Scholar
69. 1. Shahim P
    2. Zetterberg H
    3. Tegner Y
    4. Blennow K

    (2017) Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports

    Neurology 88:1788–1794.

    https://doi.org/10.1212/WNL.0000000000003912

    • PubMed
    • Google Scholar
70. 1. Sharma R
    2. Rosenberg A
    3. Bennett ER
    4. Laskowitz DT
    5. Acheson SK

    (2017) A blood-based biomarker panel to risk-stratify mild traumatic brain injury

    PLOS ONE 12:e0173798.

    https://doi.org/10.1371/journal.pone.0173798

    • PubMed
    • Google Scholar
71. 1. Shi Y
    2. Zhang L
    3. Pu H
    4. Mao L
    5. Hu X
    6. Jiang X
    7. Xu N
    8. Stetler RA
    9. Zhang F
    10. Liu X
    11. Leak RK
    12. Keep RF
    13. Ji X
    14. Chen J

    (2016a) Rapid endothelial cytoskeletal reorganization enables early blood-brain barrier disruption and long-term ischaemic reperfusion brain injury

    Nature Communications 7:10523.

    https://doi.org/10.1038/ncomms10523

    • PubMed
    • Google Scholar
72. 1. Shi M
    2. Kovac A
    3. Korff A
    4. Cook TJ
    5. Ginghina C
    6. Bullock KM
    7. Yang L
    8. Stewart T
    9. Zheng D
    10. Aro P
    11. Atik A
    12. Kerr KF
    13. Zabetian CP
    14. Peskind ER
    15. Hu SC
    16. Quinn JF
    17. Galasko DR
    18. Montine TJ
    19. Banks WA
    20. Zhang J

    (2016b) CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease

    Alzheimer's & Dementia 12:1125–1131.

    https://doi.org/10.1016/j.jalz.2016.04.003

    • PubMed
    • Google Scholar
73. 1. Shiozaki T
    2. Hayakata T
    3. Tasaki O
    4. Hosotubo H
    5. Fuijita K
    6. Mouri T
    7. Tajima G
    8. Kajino K
    9. Nakae H
    10. Tanaka H
    11. Shimazu T
    12. Sugimoto H

    (2005) Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury

    Shock 23:406–410.

    https://doi.org/10.1097/01.shk.0000161385.62758.24

    • PubMed
    • Google Scholar
74. 1. Shojo H
    2. Kaneko Y
    3. Mabuchi T
    4. Kibayashi K
    5. Adachi N
    6. Borlongan CV

    (2010) Genetic and histologic evidence implicates role of inflammation in traumatic brain injury-induced apoptosis in the rat cerebral cortex following moderate fluid percussion injury

    Neuroscience 171:1273–1282.

    https://doi.org/10.1016/j.neuroscience.2010.10.018

    • PubMed
    • Google Scholar
75. 1. Sonobe Y
    2. Takeuchi H
    3. Kataoka K
    4. Li H
    5. Jin S
    6. Mimuro M
    7. Hashizume Y
    8. Sano Y
    9. Kanda T
    10. Mizuno T
    11. Suzumura A

    (2016) Interleukin-25 expressed by brain capillary endothelial cells maintains blood-brain barrier function in a protein kinase Cϵ-dependent manner

    Journal of Biological Chemistry 291:12573.

    https://doi.org/10.1074/jbc.A109.025940

    • PubMed
    • Google Scholar
76. 1. Sun Y
    2. Jin K
    3. Childs JT
    4. Xie L
    5. Mao XO
    6. Greenberg DA

    (2004) Increased severity of cerebral ischemic injury in vascular endothelial growth factor-B-deficient mice

    Journal of Cerebral Blood Flow & Metabolism 24:1146–1152.

    https://doi.org/10.1097/01.WCB.0000134477.38980.38

    • PubMed
    • Google Scholar
77. 1. Sun Y
    2. Jin K
    3. Childs JT
    4. Xie L
    5. Mao XO
    6. Greenberg DA

    (2006) Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration

    Developmental Biology 289:329–335.

    https://doi.org/10.1016/j.ydbio.2005.10.016

    • PubMed
    • Google Scholar
78. 1. Sun XL
    2. Chen BY
    3. Zhao HK
    4. Cheng YY
    5. Zheng MH
    6. Duan L
    7. Jiang W
    8. Chen LW

    (2016) Gas1 up-regulation is inducible and contributes to cell apoptosis in reactive astrocytes in the Substantia nigra of LPS and MPTP models

    Journal of Neuroinflammation 13:180.

    https://doi.org/10.1186/s12974-016-0643-2

    • PubMed
    • Google Scholar
79. 1. Sun M
    2. Brady RD
    3. Wright DK
    4. Kim HA
    5. Zhang SR
    6. Sobey CG
    7. Johnstone MR
    8. O'Brien TJ
    9. Semple BD
    10. McDonald SJ
    11. Shultz SR

    (2017) Treatment with an interleukin-1 receptor antagonist mitigates neuroinflammation and brain damage after polytrauma

    Brain, Behavior, and Immunity 66:359–371.

    https://doi.org/10.1016/j.bbi.2017.08.005

    • PubMed
    • Google Scholar
80. 1. Tarozzo G
    2. Campanella M
    3. Ghiani M
    4. Bulfone A
    5. Beltramo M

    (2002) Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rat

    European Journal of Neuroscience 15:1663–1668.

    https://doi.org/10.1046/j.1460-9568.2002.02007.x

    • PubMed
    • Google Scholar
81. 1. Tashlykov V
    2. Katz Y
    3. Gazit V
    4. Zohar O
    5. Schreiber S
    6. Pick CG

    (2007) Apoptotic changes in the cortex and Hippocampus following minimal brain trauma in mice

    Brain Research 1130:197–205.

    https://doi.org/10.1016/j.brainres.2006.10.032

    • PubMed
    • Google Scholar
82. 1. Tashlykov V
    2. Katz Y
    3. Volkov A
    4. Gazit V
    5. Schreiber S
    6. Zohar O
    7. Pick CG

    (2009) Minimal traumatic brain injury induce apoptotic cell death in mice

    Journal of Molecular Neuroscience 37:16–24.

    https://doi.org/10.1007/s12031-008-9094-2

    • PubMed
    • Google Scholar
83. 1. Tehranian R
    2. Andell-Jonsson S
    3. Beni SM
    4. Yatsiv I
    5. Shohami E
    6. Bartfai T
    7. Lundkvist J
    8. Iverfeldt K

    (2002) Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist

    Journal of Neurotrauma 19:939–951.

    https://doi.org/10.1089/089771502320317096

    • PubMed
    • Google Scholar
84. 1. Thornhill S
    2. Teasdale GM
    3. Murray GD
    4. McEwen J
    5. Roy CW
    6. Penny KI

    (2000) Disability in young people and adults one year after head injury: prospective cohort study

    BMJ 320:1631–1635.

    https://doi.org/10.1136/bmj.320.7250.1631

    • PubMed
    • Google Scholar
85. 1. Thurman DJ
    2. Alverson C
    3. Dunn KA
    4. Guerrero J
    5. Sniezek JE

    (1999) Traumatic brain injury in the united states: a public health perspective

    Journal of Head Trauma Rehabilitation 14:602–615.

    https://doi.org/10.1097/00001199-199912000-00009

    • PubMed
    • Google Scholar
86. 1. Topcu I
    2. Vatansever S
    3. Bayram E
    4. Var A
    5. Cetin I
    6. Civi M

    (2013) The effects of lornoxicam on neuroprotection following diffuse traumatic brain injury in rats

    Turkish Neurosurgery 23:764–771.

    https://doi.org/10.5137/1019-5149.JTN.7749-13.0

    • PubMed
    • Google Scholar
87. 1. Toulmond S
    2. Rothwell NJ

    (1995) Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat

    Brain Research 671:261–266.

    https://doi.org/10.1016/0006-8993(94)01343-G

    • PubMed
    • Google Scholar
88. 1. Turbic A
    2. Leong SY
    3. Turnley AM

    (2011) Chemokines and inflammatory mediators interact to regulate adult murine neural precursor cell proliferation, survival and differentiation

    PLOS ONE 6:e25406.

    https://doi.org/10.1371/journal.pone.0025406

    • PubMed
    • Google Scholar
89. 1. Tweedie D
    2. Milman A
    3. Holloway HW
    4. Li Y
    5. Harvey BK
    6. Shen H
    7. Pistell PJ
    8. Lahiri DK
    9. Hoffer BJ
    10. Wang Y
    11. Pick CG
    12. Greig NH

    (2007) Apoptotic and behavioral sequelae of mild brain trauma in mice

    Journal of Neuroscience Research 85:805–815.

    https://doi.org/10.1002/jnr.21160

    • PubMed
    • Google Scholar
90. 1. Tweedie D
    2. Rachmany L
    3. Rubovitch V
    4. Lehrmann E
    5. Zhang Y
    6. Becker KG
    7. Perez E
    8. Miller J
    9. Hoffer BJ
    10. Greig NH
    11. Pick CG

    (2013a) Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in Hippocampus gene expression and memory deficits in mice

    Experimental Neurology 239:170–182.

    https://doi.org/10.1016/j.expneurol.2012.10.001

    • PubMed
    • Google Scholar
91. 1. Tweedie D
    2. Rachmany L
    3. Rubovitch V
    4. Zhang Y
    5. Becker KG
    6. Perez E
    7. Hoffer BJ
    8. Pick CG
    9. Greig NH

    (2013b) Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury

    Neurobiology of Disease 54:1–11.

    https://doi.org/10.1016/j.nbd.2013.02.006

    • PubMed
    • Google Scholar
92. 1. Tweedie D
    2. Fukui K
    3. Li Y
    4. Yu QS
    5. Barak S
    6. Tamargo IA
    7. Rubovitch V
    8. Holloway HW
    9. Lehrmann E
    10. Wood WH
    11. Zhang Y
    12. Becker KG
    13. Perez E
    14. Van Praag H
    15. Luo Y
    16. Hoffer BJ
    17. Becker RE
    18. Pick CG
    19. Greig NH

    (2016a) Cognitive impairments induced by concussive mild traumatic brain injury in mouse are ameliorated by treatment with phenserine via multiple Non-Cholinergic and cholinergic mechanisms

    PLOS ONE 11:e0156493.

    https://doi.org/10.1371/journal.pone.0156493

    • PubMed
    • Google Scholar
93. 1. Tweedie D
    2. Rachmany L
    3. Kim DS
    4. Rubovitch V
    5. Lehrmann E
    6. Zhang Y
    7. Becker KG
    8. Perez E
    9. Pick CG
    10. Greig NH

    (2016b) Mild traumatic brain injury-induced hippocampal gene expressions: the identification of target cellular processes for drug development

    Journal of Neuroscience Methods 272:4–18.

    https://doi.org/10.1016/j.jneumeth.2016.02.003

    • PubMed
    • Google Scholar
94. 1. Voyle N
    2. Baker D
    3. Burnham SC
    4. Covin A
    5. Zhang Z
    6. Sangurdekar DP
    7. Tan Hehir CA
    8. Bazenet C
    9. Lovestone S
    10. Kiddle S
    11. Dobson RJB

    (2015) Blood protein markers of neocortical Amyloid-β burden: a candidate study using SOMAscan technology

    Journal of Alzheimer's Disease 46:947–961.

    https://doi.org/10.3233/JAD-150020

    • Google Scholar
95. 1. Wang K
    2. Zhu X
    3. Zhang K
    4. Zhou F
    5. Zhu L

    (2016a) Gas1 knockdown increases the neuroprotective effect of glial Cell-Derived neurotrophic factor against Glutamate-Induced cell injury in human SH-SY5Y neuroblastoma cells

    Cellular and Molecular Neurobiology 36:603–611.

    https://doi.org/10.1007/s10571-015-0241-3

    • PubMed
    • Google Scholar
96. 1. Wang X
    2. Gao X
    3. Michalski S
    4. Zhao S
    5. Chen J

    (2016b) Traumatic brain injury severity affects neurogenesis in adult mouse Hippocampus

    Journal of Neurotrauma 33:721–733.

    https://doi.org/10.1089/neu.2015.4097

    • PubMed
    • Google Scholar
97. 1. Yasojima K
    2. Schwab C
    3. McGeer EG
    4. McGeer PL

    (2000) Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease

    Brain Research 887:80–89.

    https://doi.org/10.1016/S0006-8993(00)02970-X

    • Google Scholar
98. 1. Yu S
    2. Kaneko Y
    3. Bae E
    4. Stahl CE
    5. Wang Y
    6. van Loveren H
    7. Sanberg PR
    8. Borlongan CV

    (2009) Severity of controlled cortical impact traumatic brain injury in rats and mice dictates degree of behavioral deficits

    Brain Research 1287:157–163.

    https://doi.org/10.1016/j.brainres.2009.06.067

    • PubMed
    • Google Scholar
99. 1. Zanier ER
    2. Marchesi F
    3. Ortolano F
    4. Perego C
    5. Arabian M
    6. Zoerle T
    7. Sammali E
    8. Pischiutta F
    9. De Simoni M-G

    (2016) Fractalkine receptor deficiency is associated with early protection but late worsening of outcome following brain trauma in mice

    Journal of Neurotrauma 33:1060–1072.

    https://doi.org/10.1089/neu.2015.4041

    • Google Scholar
100. 1. Zarco N
     2. González-Ramírez R
     3. González RO
     4. Segovia J

     (2012) GAS1 induces cell death through an intrinsic apoptotic pathway

     Apoptosis 17:627–635.

     https://doi.org/10.1007/s10495-011-0696-8

     • PubMed
     • Google Scholar
101. 1. Zhang X
     2. Graham SH
     3. Kochanek PM
     4. Marion DW
     5. Nathaniel PD
     6. Watkins SC
     7. Clark RS

     (2003) Caspase-8 expression and proteolysis in human brain after severe head injury

     The FASEB Journal 17:1367–1369.

     https://doi.org/10.1096/fj.02-1067fje

     • PubMed
     • Google Scholar
102. 1. Zhang Y
     2. Chen K
     3. Sloan SA
     4. Bennett ML
     5. Scholze AR
     6. O'Keeffe S
     7. Phatnani HP
     8. Guarnieri P
     9. Caneda C
     10. Ruderisch N
     11. Deng S
     12. Liddelow SA
     13. Zhang C
     14. Daneman R
     15. Maniatis T
     16. Barres BA
     17. Wu JQ

     (2014) An RNA-sequencing transcriptome and splicing database of Glia, neurons, and vascular cells of the cerebral cortex

     Journal of Neuroscience 34:11929–11947.

     https://doi.org/10.1523/JNEUROSCI.1860-14.2014

     • PubMed
     • Google Scholar
103. 1. Zhang Y
     2. Yao XY
     3. Gao MC
     4. Ding J
     5. Hong RH
     6. Huang H
     7. Zhuang L
     8. Wang YG
     9. Hao Y
     10. Guan YT

     (2018) Th2 axis-related cytokines in patients with neuromyelitis optica spectrum disorders

     CNS Neuroscience & Therapeutics 24:64–69.

     https://doi.org/10.1111/cns.12774

     • PubMed
     • Google Scholar
104. 1. Ziebell JM
     2. Bye N
     3. Semple BD
     4. Kossmann T
     5. Morganti-Kossmann MC

     (2011) Attenuated neurological deficit, cell death and lesion volume in Fas-mutant mice is associated with altered neuroinflammation following traumatic brain injury

     Brain Research 1414:94–105.

     https://doi.org/10.1016/j.brainres.2011.07.056

     • PubMed
     • Google Scholar
105. 1. Zohar O
     2. Schreiber S
     3. Getslev V
     4. Schwartz JP
     5. Mullins PG
     6. Pick CG

     (2003) Closed-head minimal traumatic brain injury produces long-term cognitive deficits in mice

     Neuroscience 118:949–955.

     https://doi.org/10.1016/S0306-4522(03)00048-4

     • PubMed
     • Google Scholar
106. 1. Zvejniece L
     2. Stelfa G
     3. Vavers E
     4. Kupats E
     5. Kuka J
     6. Svalbe B
     7. Zvejniece B
     8. Albert-Weissenberger C
     9. Sirén AL
     10. Plesnila N
     11. Dambrova M

     (2020) Skull fractures induce neuroinflammation and worsen outcomes after closed head injury in mice

     Journal of Neurotrauma 37:295–304.

     https://doi.org/10.1089/neu.2019.6524

     • PubMed
     • Google Scholar

Author details

1. David Tweedie

   Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, NIH, Baltimore, United States

   Contribution

   Conceptualization, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing

   Contributed equally with

   Hanuma Kumar Karnati

   For correspondence

   tweedieda@grc.nia.nih.gov

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-8446-4544

2. Hanuma Kumar Karnati

   Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, NIH, Baltimore, United States

   Contribution

   Formal analysis, Investigation

   Contributed equally with

   David Tweedie

   Competing interests

   No competing interests declared

3. Roger Mullins

   Laboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH, Baltimore, United States

   Contribution

   Formal analysis, Methodology, Writing - original draft, Writing - review and editing

   Competing interests

   No competing interests declared

4. Chaim G Pick

   Department of Anatomy and Anthropology, Sackler School of Medicine, Sylvan Adams Sports Institute, and Dr. Miriam and SheldonG. Adelson Chair and Center for the Biology of Addictive Diseases, Tel Aviv University, Tel Aviv, Israel

   Contribution

   Conceptualization, Writing - original draft

   Competing interests

   No competing interests declared

5. Barry J Hoffer

   Department of Neurosurgery, Case Western Reserve University School of Medicine, Cleveland, United States

   Contribution

   Conceptualization, Writing - original draft, Writing - review and editing

   Competing interests

   No competing interests declared

6. Edward J Goetzl

   Department of Medicine, University of California Medical Center, San Francisco, San Francisco, United States

   Contribution

   Writing - original draft, Writing - review and editing

   Competing interests

   No competing interests declared

7. Dimitrios Kapogiannis

   Laboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH, Baltimore, United States

   Contribution

   Writing - original draft, Writing - review and editing

   Competing interests

   No competing interests declared

8. Nigel H Greig

   Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, NIH, Baltimore, United States

   Contribution

   Conceptualization, Resources, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-3032-1468

• 2,668

  views

• 350

  downloads

• 28

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.